Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,980.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00. Following the completion of the sale, the president now owns 2,901,138 shares in the company, valued at $30,432,937.62. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.

Gyre Therapeutics Price Performance

Shares of NASDAQ:GYRE opened at $11.74 on Wednesday. The stock’s 50-day moving average price is $11.12 and its two-hundred day moving average price is $12.57. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently modified their holdings of GYRE. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter worth approximately $47,000. Barclays PLC grew its stake in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $123,000. Renaissance Technologies LLC purchased a new position in shares of Gyre Therapeutics in the 2nd quarter worth $166,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in shares of Gyre Therapeutics in the 3rd quarter worth $334,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.